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INTRODUCTION 
 
August Bier was the first person to introduce spinal anesthesia on 
16-08-1898 using 0.5 cocaine which is the first known local anesthetic. 
Spinal anaesthesia has a long history of success in producing profound 
nerve block in a large part of the body by the relatively simple injection 
of a small amount of local anaesthetic. 
 
 The choice of local anaesthetics is determined by the duration of 
surgery and by the intensity of motor blockade that is required. 
Lignocaine was the first amide local anaesthetic and it replaced esters 
following its clinical introduction in the early 1950’s. Lignocaine does 
not have allergic sensitization, seen with esters. Lignocaine was  
extensively used local anaesthetic for spinal anaesthesia, but now the 
use has fallen dramatically due to concerns regarding transient 
neurological symptoms.  
 
This prompted search for alternatives. Bupivacaine is the first 
long acting amide local anaesthetic. Its advantage when compared to 
lignocaine is its  longer duration of action and differential sensory motor 
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block. It is due to increased lipid solubility and protein binding. But it 
has lower therapeutic index with respect to cardiovascular toxicity.  
 
The increase in day care surgery has generated a need for a local 
anaestheic with a quick onset and shorter duration of action allowing 
early ambulation. Moreover, the major concern about the cardiotoxicity 
of bupivacaine has led to the development of ropivacaine, a new long 
acting amide. It is a part of the homologous series that includes 
bupivacaine and mepivacaine. It has an isopropyl group bound to 
piperdine nitrogen in place of mepivacaine’s, methyl group and 
bupivacaine’s butyl group. It is manufactured as pure s-enantiomer 
rather than a racemic mixture. 
 
 The L form is less cardiotoxic and has shorter duration of action 
than bupivacaine. Its low lipid solubility resulted in reduced risk of 
negative inotropism and decreased affinity for cardiac sodium channels 
than bupivacaine. Thus it has an improved safety profile over 
bupivacaine. It is available in isobaric, hyperbaric forms. The major 
clinical advantage of isobaric solution is that the patient’s position 
during and after injection have no effect on the spread of local 
anaesthetic in cerebrospinal fluid. Thus isobaric solution do not tend to 
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distribute as far from the site of injection. It is useful when lower 
thoracic dermatomal sensory block is desired and when degree of 
sympathetic blockade needs to be minimized.  
 
Hence the present study has been undertaken to compare the 
efficacy  and hemodynamic effects  of isobaric bupivacaine and isobaric 
ropivacaine for lower abdominal surgeries.       
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AIM OF THE STUDY 
 
The purpose of this study is to compare the anesthetic efficacy of 
intrathecal isobaric ropivacaine 0.5% with bupivacaine 0.5% in lower 
abdominal surgeries with respect to 
a. Onset and duration of sensory block 
b. Onset, quality and duration of motor block 
c. Hemodynamic changes 
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ANATOMY 
 
         Spinal (subarachnoid / intrathecal) anaesthesia is a form of central 
neuraxial block in which a temporary interruption of neural transmission 
is achieved following injection of local anaesthetic and/or adjuvant 
solutions into the subarachnoid space. Spinal anaesthesia is one of the 
most frequently employed techniques of regional anaesthesia. 
 
The vertebral canal extends from the foramen magnum to the 
sacral hiatus. It is formed by the dorsal spine, pedicles and lamina of 
successive vertebrae (7 cervical, 12 thoracic, 5 lumbar and 5 sacral). The 
vertebrae are held together by a series of overlapping ligaments namely 
the anterior and posterior longitudinal ligaments, ligamentum flavum, 
interspinous ligament, supraspinous ligament and the intervertebral 
discs. 
 
The spinal cord, a direct continuation of the medulla oblongata 
begins at the upper border of the atlas and terminates distally in the 
conus medullaris. The distal termination, because of the differential 
growth rates between the bony vertebral canal and central nervous 
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system varies from L3 in the infant, to the lower border of LI in the 
adult. 
 
Surrounding the spinal cord in the bony vertebral column are 
three membranes (from within to the periphery), the piamater, arachnoid 
mater and duramater. The pia mater is a highly vascular membrane that 
closely invests the spinal cord. The arachnoid mater is a delicate 
neovascular membrane closely attached to the outermost duramater.  
Between the two innermost membranes is the subarachnoid space. In 
this space are the cerebrospinal fluid, spinal nerve roots, blood vessels 
that supply the spinal cord and the denticulate ligaments. Although the 
spinal cord ends at the lower border of LI in adults, the subarachnoid 
space continues to S2. The outermost membrane in the spinal canal is 
the longitudinally organized fibro elastic membrane, the duramater. This 
layer is the direct extension of the cranial duramater and extends as the 
spinal duramater from the foramen magnum to S2, where the filum 
terminale (an extension of the piamater beginning at the conus 
medullaris) blends with the periosteum of the subdural space which 
contains only small amounts of serous fluids to allow the dura and 
arachnoid move over each other.  
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Surrounding the duramater is the epidural space which extends 
from the foramen magnum to the sacral hiatus. Posterior to the epidural 
space is the ligamentum flavum which extends from the foramen 
magnum to the sacral hiatus. It runs from the anterior and inferior 
aspects of the lamina above to the posterior and superior aspect of the 
lamina below. Immediately posterior to the ligamentum flavum is the 
interspinous ligament. Extending from the external occipital 
protuberance to the coccyx, posterior to these structures is the 
supraspinous ligament. Lumbar puncture is routinely done below the L2 
vertebrae down to the L5-S1 interspace to avoid damaging the spinal 
cord which ends at the lower border of LI in adults. 
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PHYSIOLOGY OF SUBARACHNOID BLOCK 
 
 
The cerebrospinal fluid (CSF) is an ultrafiltrate of blood plasma 
with which it is in hydrostatic and osmotic equilibrium. It is a clear, 
colourless fluid found in the spinal and cranial subarachnoid space and 
in the ventricles of the brain. The average volume in the adult ranges 
from 120-150 ml of which 35 ml is in the ventricles, 25 ml is in the 
cerebral subarachnoid space and 75 ml is in the spinal subarachnoid 
space. It is secreted by the choroid plexus at a rate of 0.3-0.4 ml/minute. 
 
Physical Characteristics of Cerebrospinal Fluid: 
 
PH 7.4 
Specific gravity (H20) At body 
temperature At4°C 
1.007  
1.0003 
Density 1.0003g/ml 
Baricity 1.000 
Pressure in supine position 8-12mm Hg 
Cells 3-5/cu.mm 
Proteins 20 mg/dl 
Glucose 45-80 mg/dl 
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The cerebrospinal fluid plays an important role in spinal 
anesthesia as media for dispersion of the local anesthetic drug to the 
spinal nerve. An important factor determining the spread of drugs in the 
subarachnoid space is the specific gravity of the injected solution 
compared with that of CSF. 
 
MECHANISM OF SPINAL ANAESTHESIA 
 
Injection of local anaesthetic solution into the spinal CSF allows 
access to sites of action both within the spinal cord and the peripheral 
nerve roots. The nerve roots leaving the spinal canal are not covered by 
epithelium and are readily exposed to the local anaesthetic within the 
CSF. Therefore afferent impulses leaving via the ventral nerve roots are 
blocked during spinal anaesthesia. Local anaesthetics block sodium 
channels and propagation of action potential in spinal nerve roots. There 
are also multiple potential actions of local anaesthetics within the spinal 
cord at different sites. Local anaesthetics can exert sodium channel 
block with in the dorsal and ventral horns, inhibiting generation and 
propagation of electrical activity.  
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Zone of Differential Blockade:  
Sensory: 
In Subarachnoid block sympathetic fibers are blocked two to three 
segments higher than sensory fibers. Sympathetic block will be greater 
when more concentrated solutions are used or when adrenaline is added, 
as this has a similar effect. 
 
Order of blocking nerve fibers: 
1. Autonomic preganglionic  B fibers. 
2. Temperature fibers- Cold before warm. 
3. Pinprick fibers. 
4. Fibers conveying pain greater than pin prick. 
5. Touch fibers. 
6. Deep pressure fibers. 
7. Somatic motor fibers. 
8. Fibers conveying vibratory sense and proprioceptic impulses. 
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During recovery, sensations return in the reverse order, but it has 
been suggested that sympathetic activity returns before sensation. 
 
SPREAD OF LOCAL ANAESTHETICS IN SUBARACHNOID 
SPACE 
 
The local anaesthetic solution is diluted by CSF and therefore its 
original concentration is of less than the actual mass of drug injected. 
Spread is also determined by the baricity of the injected solution. 
Baricity is a ratio comparing the density of a local anaesthetic solution at 
a specified temperature to the density of CSF at the same temperature. A 
hypobaric solution has a baricity less than 1.0000 or specific gravity less 
than 1.0069 (the mean value of specific gravity). A hyperbaric solution 
has a baricity greater than 1.0000 or specific gravity more than 1.0069. 
Hypobaric and Hyperbaric solutions are prepared from isobaric 
solutions by the addition of various amounts of sterile distilled water 
and dextrose respectively. Isobaric solutions do not move under the 
influence of gravity in the CSF. Hyperbaric solutions, being heavier than 
CSF, settle to the most dependent aspect of the subarachnoid space, 
which is determined by the position of the patient. In supine patient, 
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hyperbaric solutions gravitate to the thoracic kyphosis. Hypobaric 
solution floats up against the gravity to the nerves innervating the 
surgical site.  
 
FATE OF LOCAL ANAESTHETICS IN SUBARACHNOID 
SPACE 
 
Following injection of local anaesthetic solution into 
subarachnoid space, its concentration falls rapidly. The initial steep fall 
is due to mixing with CSF and subsequent absorption into nerve roots 
and spinal cord. The egress of local anaesthetic solution following 
subarachnoid injection is primarily by vascular absorption. Depending 
on the type of the drug used, it is metabolized in plasma by pseudo 
cholinesterase or in the liver. As duration of anaesthesia is in part, a 
result of the rate of absorption from the subarachnoid space, the addition 
of a vasoconstrictor to the local anaesthetic solution will retard 
absorption of the drug and thus increase the duration of anesthesia. 
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INDICATIONS FOR SUBARACHNOID BLOCK 
 
Spinal anaesthesia can be administered for surgeries below 
umbilicus.  
 
• Lower abdominal surgeries, 
• Lower limb surgeries, 
• Urological procedures, 
• Obstetric procedures, 
• Gynecological surgeries, 
• Perineal and rectal surgeries. 
 
CONTRAINDICATIONS FOR SUBARACHNOID BLOCK 
Absolute contraindication: 
 
• Patient refusal.  
• Local sepsis. 
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Relative contraindications: 
• Coagulopathy. 
• Fixed cardiac output states. 
• Documented allergy to local anesthetics. 
• Raised intracranial pressure. 
• Neurological disease. 
• Major spine deformities/previous surgery on the spine. 
• Severe cardiac disease. 
 
FACTORS INFLUENCING HEIGHT OF ANALGESIA IN 
SUBARACHNOID BLOCK 
 
• Dose of the drug injected. 
• Volume of fluid injected. 
• Specific gravity of the solution. 
• Position of the patient during injection. 
• Posture of patient after injection. 
• Choice of interspace. 
• Patient factors- Age, Height, Pregnancy. 
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FACTORS NOT INFLUENCING HEIGHT OF ANALGESIA IN 
SUBARACHNOID BLOCK 
 
• Patient factors- Weight, Sex. 
• Barbatoge. 
• Rate of injection. 
• Composition and circulation of cerebrospinal fluid. 
• Direction of bevel of the standard needle (although not of the 
Whitacare needle). 
 
COMPLICATIONS OF SUBARACHNOID BLOCK 
Immediate:  
• Hypotension. 
• Bradycardia. 
• Toxicity due to intravascular injection. 
• Allergic reaction to local Anesthetic. 
• Hypoventilation (brain stem hypoxia). 
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Late: 
• Post dural Puncture head ache. 
• Retention of urine. 
• Back ache. 
• Meningitis. 
• Transient lesions of cauda equina 
• Sixth nerve palsy. 
• Anterior spinal artery syndrome. 
• Horner's syndrome.  
 
 
CIRCULATORY EFFECTS OF SUBARACHNOID BLOCK 
 
The subarachnoid block can influence the cardiovascular system, 
as follows. 
1) Vasodilatation of resistance and capacitance vessels. 
2) Block of cardiac efferent sympathetic fibers from T1 to T4 
resulting in loss of chronotropic and inotropic drive and fall in 
cardiac output. 
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3) A further cause of bradycardia is the lowering of pressure in the 
right atrium consequent to diminished venous return (Bain Bridge 
reflex). 
4) The operation of Marey's law causing tachycardia. 
5) Vasodilatation and β-adrenergic blockade of myocardium with 
fall in cardiac output, following systemic absorption of the local 
anaesthetic drug. 
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PHARMACOLOGY OF BUPIVACAINE 
 
Bupivacaine is an amide linked local anaesthetic. It is a 
hydrochloride of d(1)-1-butyl 2’6’ pipecoloxylidide and is present as  a 
racemic mixture. 
 
 
 
 It was synthesized by Eoaf Ekentem. First reports of its use was 
published in 1965 by Telinko. It’s a very stable compound and may be 
autoclaved repeatedly. Its pk is 8.1, molecular weight -288, protein 
binding 95%, lipid solubility 28%, elimination half life-210 minutes, 
toxic plasma concentration greater than 1.5 microgram/ml and 
approximate duration of action is 175 minutes. 
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AVAILABILITY 
Ampoule-0.5% bupivaciane hydrochloride, 4cc with dextrose 
                 -0.5% bupivacaine hydrochloride 20cc isobaric 
Vials-0.25% and 0.5% bupivacaine hydrochloride 20cc 
The maximum dose is 3mg/kg body weight 
 
USES 
Spinal anaesthesia 
Epidural anaesthesia 
Caudal anaesthesia 
Continuous epidural anaesthesia 
Peripheral nerve block 
Local infiltration 
 
PHARMACOKINETICS 
Once injected intrathecally, it gets absorbed by the nerve rootlets 
and results in the desired effect. It is rapidly absorbed from the site of 
injection, but the rate of absorption depends on the vascularity at the site 
and presence of vasoconstriction. High lipid solubility of bupivacaine 
makes it easy for nerve and vascular tissue penetration. 
80 to 85% of the absorbed bupivacaine gets into the plasma. 
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DISTRIBUTION 
Rapid distribution phase(alpha)-in this phase the drug is 
distributed to highly vascular region  half time being 2.7 minutes. 
Slow disappearance phase(beta)-in this phase the drug distributes 
and slowly equlibriating tissues half time of Beta  is 28 minutes. 
Biotransformation and excretion phase- half time of γ  is 3.5 
hours. 
 
BIOTRANSFORMATION 
Possible pathways of metabolism of bupivacaine include aromatic 
hydroxylation and conjugation. Only the N-alkylated metabolite, N-
butyl bupivacaine has been measured in blood or urine after epidural or 
spinal anaesthesia. Alpha acid glycoprotein is the most important plasma 
protein binding site of bupivacaine. 
Excretion is through the kidney .4-10% of the drug is excreted 
unchanged. 
 
MODE OF ACTION 
a) Site of action-The spinal nerve rootlet fine nerve filaments 
having a large surface area are exposed to local anaesthetics. 
b) Posterior and lateral aspects of the spinal cord 
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c) Sodium channel blockade-they impede sodium  ion access to 
the axon interior by occluding the transmembrane sodium 
channels thus delaying the process of depolarization and axon 
remains polarized.  
 
PHARMACODYNAMICS 
 
CARDIOVASCULAR SYSTEM 
Bupivacaine reduces cardiac output by reducing the sympathetic 
tone, by slowing the heart rate and by reducing the venous return, it 
produces a fall in arterial blood pressure but it is relatively slow and 
seldom it is very profound. It produces a fall in central venous pressure. 
It causes an increase in lower limb blood flow. It causes a reduction in 
incidence of deep vein thrombosis. 
 
GASTROINTESTINAL TRACT 
There is an increase in GIT motility. 
 
TOXICITY 
Toxicity is related to plasma level of unbound drug and more 
likely due to inadvertent intravenous injection. Systemic toxicity 
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reactions primarily involve CNS and CVS. The blood level required to 
produce CNS toxicity is less than that to produce circulatory collapse. 
 
CENTRAL NERVOUS SYSTEM TOXICITY 
Initial symptoms include feeling of light headedness and 
dizziness, followed by visual and auditory disturbances. Objective signs 
are excitatory, muscle twitching and tremor, ultimately generalized tonic 
clonic seizure occurs. 
 
CARDIOVASCULAR TOXICITY 
The state of depolarization in fast conducting tissue of purkinge 
fibres of ventricular muscle is decreased. The rate of recovery of 
bupivacaine induced block is slower than that of lignocaine. Extremely 
high concentrations of the drug causes bradycardia and cardiac arrest.  
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PHARMACOLOGY OF ROPIVACAINE 
In 1957, Ekenstam synthesized ropivacaine it’s a new aminoamide local 
anaesthetic. It is s-1-propyl 2-6-pipecoloxylide hydrochloride mono 
hydrate, introduced clinically in 1996 has propyl group in piperdine 
nitrogen atom. It is long acting local anaesthetic, causes differential 
sensory and motor block. The rate depends on physiochemical 
properties-high pka and lipid solubility.pka is 8.1, lipid solubility and 
partial coefficient is 2.9. 
 
Pka of bupivacaine and ropivacaine are identical, but ropivacaine 
is less fat soluble predicting that ropivacaine will block A fibres more 
slowly than bupivacaine. 
It has chiral centre in piperidine ring with propyl group attached 
to nitrogen. It is single levo isomer s(-) enantiomer which has no 
asymmetric carbon. It is structurally related to bupivacaine and 
mepivacaine. It has dissociation constant of 8.1, protein binding of 90-
 25
94%, lipid solubility is less than one half of bupivacaine, molecular 
weight of 328.89, weak vasoconstrictor. 
 
MECHANISM OF ACTION 
The clinical profile is similar to that of bupivacaine. It elicits 
nerve block via reversible inhibition of sodium ion influx in nerve 
fibres. This is potentiated by dose dependent inhibition of potassium 
channels. It blocks A delta and c fibres than motor fibres(being less 
lipophyllic).It has little motor block thus producing less incidence of 
deep thrombosis and better  respiratory mechanics.  
It is available in 0.2%, 0.5%, 0.75% and1% solution the 
maximum dose is  3mg per kg body weight and the toxic plasma 
concentration is 4 meq/L.   
 
Dosage recommendations for ropivacaine in adults and children 
 
Indication and procedure Concentration (%) Volume Dose 
In adults 
Surgical anaesthesia 
Lumbar epidural (caesarean section) 
Lumbar epidural (other surgery) 
 
Thoracic (single block for postoperative pain 
relief) 
Intrathecal administration 
Peripheral nerve block 
Field block 
Postoperative pain 
 
 
0.75 
0.75 
1 
0.75 
 
0.5 
0.75 
0.75 
 
 
 
15-20 mL 
15-25mL 
15-20mL 
5-15mL 
 
3-4mL 
10-40mL 
1-30mL 
 
 
 
113-150mg 
113-188mg 
150-200mg 
38-113mg 
 
15-20mg 
75-300mg 
7.5-225mg 
 
 26
Lumbar epidural (continuous infusion) 
Thoracic epidural (continuous infusion) 
Peripheral nerve block (continuous infusion) 
Filed block 
Intra-articular injection 
Labour pain (lumbar epidural) 
Bolus 
Intermittent top-ups 
Continuous infusion 
In children  
Caudal epidural block (below T12) 
(For bodyweight up to 25kg) 
Peripheral nerve block (e.g. ilioinguinal nerve 
block) 
0.2 
0.2 
0.2 
 
0.2 
0.75 
 
0.2 
0.2 
0.2 
 
0.2 
 
0.5 
6-10mL/h 
6-14mL/h 
5-10mL/h 
 
1-100mL 
20mL 
 
10-20mL 
10-15mL 
6-14mL/h 
 
1mL/kg 
 
0.6mL/kg 
12-20mg/h 
12-28mg/h 
10-20mg/h 
 
2-200mg 
150mg 
 
20-40mg 
20-30mg 
12-28mg/h 
 
2mg/kg 
 
3mg/kg 
 
 
PHARMACOKINETICS-ABSORPTION AND DISTRIBUTION 
The plasma concentration of ropivacaine depends on the total 
dose administered and the route of administration as well as the 
hemodynamic condition of the patient and the vascularity of the 
administered site. Ropivacaine is 94% bounded to alpha-1 acid 
glycoprotein. The duration of action depends on protein binding and 
clearance from the injection site. The volume of distribution of steady 
state is 59 litres; with a clearance ratio 0.73, hepatic extraction ratio of 
0.4.The systemic toxicity is considered to be related to unbound drug 
concentration. The change in protein binding occurs with increase in 
plasma alpha acid glyco protein that accompanies the stress response to 
 27
surgery. Ropivacaine crosses the placenta but the foetal concentration is 
lower than maternal circulation. 
 
OTHER EFFECTS 
Ropivacaine inhibits platelet aggregation in plasma at 
concentration of 3.75 mg/ml. It has antibacterial activity in vitro 
inhibiting the growth of staphylococcus aureus, pseudomonas 
aeruginosa, E.coli.  
 
 
ADVERSE EFFECTS  
Hypotension, nausea, bradycardia, backpain, vomiting, headache, 
fever, chills, urinary retention, pruritus. 
 
METABOLISM AND ELIMINATION 
Ropivacaine is metabolised in liver by aromatic hydroxylation 
to3’-hydroxy-ropivacaine and N–deaikylation to 2’-6’-pipecoloxylidide. 
Other metabolites includes4’-hydroxy ropivacaine and 2’ hydroxy- 
methyl-ropivacaine. About 1-2% of drug is eliminated as unchanged in 
urine. 
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TOXICITY 
Central nervous system toxicity is directly related to local 
anaesthetic potency and the convulsant doses of ropivacaine and 
bupivacaine are similar. Local anaesthetics exert their direct toxic 
effects on heart by blocking sodium influx through sodium channels. 
This causes depression of maximal rate of increase (Vmax) of cardiac 
action potential and results in delayed conduction, ropivacaine depress 
Vmax less than bupivacaine and recovery is quicker after ropivacaine. 
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MATERIAL AND METHODS 
 
After approval of the study by  the Institutional Ethical 
Committee the study was conducted in , 100 ASA physical status I-II 
patients, undergoing elective lower abdominal surgery under spinal 
anesthesia. The age of the patients ranged from 23-68 yrs weighing 35-
65kgs and height ranging from 150-168 cms. All patients were 
thoroughly examined preoperatively. Informed written consent was 
obtained and the procedure was explained. All patients weight, height 
were noted. 
 
In the assessment room, vital parameters like pulse rate, blood 
pressure and baseline investigations like Haemoglobin, urine analysis 
for albumin, sugar ,blood sugar urea, creatinine and ECG were checked. 
Thorough examination of all the system and airway assessment was 
done. 
Exclusion criteria included, local infection, bleeding disorder. The 
patients were randomly allocated into two groups of 50 each. 
Group A patients received 3ml of 0.5% isobaric ropivacaine 
(15mg).  
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Group B patients received 3ml of .5% isobaric bupivacaine 
(15mg) 5mg/ml. 
The total volume of the injected solution was 3ml in both groups. 
In the operating room, appropriate equipment for airway management 
and emergency drugs were kept ready. Patients were shifted to the 
operating room. The horizontal position of the operating table was 
checked. NIBP monitor, Pulseoximetry and ECG leads were connected 
to the patient. Preoperative baseline mean arterial pressure, pulse rate 
and O2 saturation were recorded. Patients were cannulated with 18G 
intravenous cannula and preloaded with 1000 ml of ringer lactate. The 
patients were placed in right lateral position. The skin over the back was 
prepared with antiseptic solution and draped with sterile towel. Lumbar 
puncture was performed with a25G spinal needle at L2-L3 or L3-L4 
interspace via midline approach. After confirming free flow of CSF, the 
drug was injected. The patients were made to lie supine immediately 
after injection and the time at which the drug injected was noted. 
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THE FOLLOWING PARAMETERS WERE OBSERVED 
Sensory block 
The onset of sensory block was defined as the time between the 
injection of anaesthetic solution and the absence of pain to pinprick at 
the T10 dermatome. Sensory block was assessed by loss of sensation. 
(pin prick sensation using 21G sterile needles) bilaterally along the 
midclavicular line. This assessment started immediately after turning the 
patient supine and continued every minute till the peak block height was 
reached and the time was noted. The duration of sensory block was 
defined as the time for regression of two segments from the maximum 
level of sensory block height evaluated by the pinprick. Sensory block 
was checked every 15 mts till it reached two segment regression. 
 
MOTOR BLOCK  
Motor block was assessed bilaterally using Modified Bromage scale. 
 
MODIFIED BROMAGE SCALE. 
0-no block, able to raise extended legs against gravity.  
1-unable to raise extended leg, but just able to flex knees. 
2-unable to flex knees, but able to flex ankles 
3-Total block-inability to flex ankle 
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Assessment of motor block was started immediately after turning 
the patient supine and continued every minute till Bromage score of 3 
was reached. The onset of motor block was defined as the time to 
achieve Bromage score of 3 from the time of injection. Duration for 
complete motor block recovery was taken as the time from 
subarachinoid injection to return of Bromage score to zero. 
 
VITAL SIGNS AND SIDE EFFECTS 
Mean arterial pressure, pulse rate  were recorded every two 
minutes for the first 10 mts and thereafter every 5 mts until the 
immediate post operative period Oxygen saturation monitored 
continuously. Hypotension was defined as a fall in systolic blood 
pressure more than 30% from baseline or systolic blood pressure less 
than 90mm Hg. This was managed by incremental doses of 6mg 
intravenous ephedrine. 
 
Bradycardia was defined as heart rate less than 60/mt and 
managed by incremental doses of 0.3mg intravenous atropine. 
Respiratory depression was said to be present if respiratory rate was less 
than 8 /mt and SP02 less than 85%. The respiratory arrest was managed 
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with intubation and IPPV. Vomiting was managed with metaclopramide 
10 mg intravenously. Pruritis was managed with reassurance or by 
pheniramine maleate 22.75 mg. Urinary retention was monitored 
postoperatively and catheterization was planned in patients with 
prolonged retention more than 6 hours. Patients were shifted to recovery 
room after completion of surgery.              
 
STATISTICAL TOOLS 
The information collected regarding all the selected cases were 
recorded in a Master Chart. Data analysis was done with the help of 
computer using Epidemiological Information Package.  
 
 Using this software range, frequencies, percentages, means, 
standard deviations, chi square and 'p' values were calculated. Kruskul 
Wallis chi-square test was used to test the significance of difference 
between quantitative variables.  The 'p' value less than 0.05 is taken to 
denote significant relationship. 
 
 
 34
REVIEW OF LITERATURE 
 
P.D.W.Fettes, G.Hocking et. al., conducted double blinded 
prospective randomised study in 40 patients undergoing elective 
perineal surgery under spinal anaethesia. They received either 15mg of 
plain ropivacaine or 15mg of  hyperbaric ropivacaine.  He reported that 
intrathecal plain ropivacaine produced satisfactory analgesia. The study  
showed the cephalic spread to T8 in plain and T4 in hyperbaric group 
respectively. There was a significant difference in the onset of sensory 
block to T10 of about 10 minutes for plain and 5 minutes for hyperbaric 
groups respectively. The motor regression time are 180 minutes for 
plain and 120 minutes for hyperbaric groups respectively, showing 
hyperbaric ropivacaine produced more rapid onset of motor block which 
ultimately regress more quickly.    
      
M. Mantouvalou S Rali et al in their study compared the 
anaesthetic efficacy and safety of 3 local anaesthetic agents namely 
15mg of  racemic bupivacaine, ropivacaine and levobupivacaine in 
patients undergoing lower abdominal surgeries. It stated that cephalic 
spread of sensory block was similar in all groups with onset of motor 
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block in bupivacaine is 8 ± 5 minutes and ropivacaine 12 ± 5 minutes. 
Thus it showed faster onset with bupivacaine and shorter duration of 
motor block in ropivacaine of 100 ± 34 minutes when compared to 
bupivacaine of 150 ± 40 minutes.  
 
H.Kallio, E,V.T Snall et. al., in the prospective randomized 
double blinded study in 90 ambulatory lower extremity surgery patients 
who received 2 ml of isobaric ropivacaine 1%, 0.75% and isobaric 0.5% 
bupivacaine. It showed adequate block level with hemodynamic stability 
and faster motor recovery of about 137.2 minutes in ropivacaine when 
compared to bupivacaine (204.4 minutes).  
 
Jean-Marc., Malinovsky, Florence Charles, Ottman Kiel et al 
compared 15mg of intrathecal isobaric ropivacaine with 10mg isobaric 
bupivacaine in patients scheduled for transurethral resection of bladder 
or prostate. The cephalic spread in bupivacaine is T7 and ropivacaine is 
T9. The onset of motor block of ropivacaine is 11 minutes and its 
recovery is 105 ± 25 minutes where as in bupivacaine 13 ± 8 minutes 
and  127 ± 17 minutes respectively. No difference in hemodynamic 
effects was detected between the two groups.  
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Kim, S. Khaw, Warwick d.ngen kee et al conducted a 
comparative study of 25 mg spinal hyperbaric and isobaric solution of 
ropivacaine in caesarean sections.  It showed more extensive spread 
(T4), faster onset of motor block (7.7 minutes) and its faster recovery 
(144 minutes) in hyperbaric group than isobaric ropivacaine (T7 and 
13.8 minutes, 184 minutes)and reported the onset of sensory block of 
11.4 mins and its duration 216 mins .    
 
D.A. McNamee, A.M.Mc Clellana, S.Scot et. al., in their 
comparative study of the efficacy and safety of 17.5mg of plain 
ropivacaine with 17.5mg of plain bupivacaine for spinal anaesthesia in 
patients undergoing total hip arthroplasty stated that there was a trend 
for patients in bupivacaine to achieve higher upper dermatomal level of 
sensory block but this difference was not significant. There was no 
significant difference in the median time of onset of sensory block at 
T10 dermotome which was 2 minutes with ropivacaine and bupivacaine. 
Duration of sensory block longer in bupivacaine (3.5 hours) compared 
to ropivacaine (3 hours). There is a shorter duration of  motor block in 
ropivacaine 2.1 hours versus 3.9 hours in bupivacaine.   
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P. Gautier M. Dekock L. Huberty T Demir compared the effects 
of intrathecal isobaric ropivacaine, levobupivacaine and bupivacaine for 
caesarean section in 90 parturients. Combined spinalepidural technique 
was used with bupivacaine (8mg), leveobupivacaine (8mg), ropivacaine 
(12mg) all combined with sufentanil 2.5microgram. In the study, the 
onset and duration of motor block in bupivacaine  was 9 and 142 
minutes and with ropivacaine 14 and 116 minutes, showing shorter 
duration of  motor block with ropivacaine. The duration of sensory 
block with bupivacaine was 145 minutes and ropivacaine was 135 
minutes.     
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OBSERVATION AND RESULTS 
 
 All 100 patients in two groups completed the study without any 
exclusion. We did an inter group analysis and the results were as 
followed. Of the 100 patients 50 belonged to Group A (ropivacaine) and 
other 50 categorized as Group B(bupivacaine). Data were presented as 
range, mean, standard deviation. The probability value ‘P’ of less than 
0.05 considered statistically significant.  
 39
Table 1 : AGE DISTRIBUTION 
Age group 
 
Group A Group B 
No. % No. % 
Less than  20 yrs 2 4 1 2 
20-29 yrs 11 22 5 10 
30 – 39 yrs 12 24 11 22 
40 – 49 yrs 14 28 14 28 
50-59 years 6 12 11 22 
60 years & above 5 10 8 16 
Total 50 100 50 100 
Range 
Mean 
S.D. 
Value 
19 – 66 years 
40.0 years 
13 0 years 
40 ±13 
19 – 68 years 
45 years 
12.5  years   
45 ±12.5  
‘p’ 0.0543 
Not significant 
Patients demographic data between the two group were 
comparable. In table1 illustrated the age distribution in the range of 19-
66 years in Group A and 19-68 years in Group B. The mean, age was 
statiscally similar. ‘p’ value is 0.543. which was statistically 
insignificant.  
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Table 2 : SEX DISTRIBUTION 
 
 
Sex 
Group A Group B 
No. % No. % 
Male 35 70 36 72 
Female 15 30 14 28 
Total 50 100 50 100 
‘p’ 0.8264 
Not significant 
 
Table 2 represents sex distribution in our study. Of the 100 
patients 71 were male and 29 were female. Group A has 70% male and 
30% female. Group B has 72% male and 28% female.  The distribution 
was similar in both groups. The p value is 0.8264 which was 
insignificant.  
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TABLE 3 :  
 
DURATION OF SURGERY  (IN MINUTES) 
 
Duration of Surgery 
(in minutes) 
 
Group A 
 
Group B 
Range 
Mean 
S.D. 
Value 
45– 160 minutes 
94 minutes 
22.2 minutes 
94 ± 22.2 
45 – 125 minutes 
97.4 minutes 
12.9 minutes 
97.4 ± 12.9 
‘p’ 0.4924 
Not Significant 
 
 
 
The average duration of surgery in both groups were comparable. The 
‘p’ value of 0.4924 which was not significant. 
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Table 4 : PEAK SENSORY LEVEL 
 
Peak Sensory Level 
Group A Group B 
No. % No. % 
T2 - - - - 
T4 1 2 - - 
T6 1 2 16 32 
T8 45 90 34 68 
T12 3 6 - - 
Total 50 100 50 100 
 
 
In this table the distribution of upper extend of sensory block in both 
groups were given. T10, the ideal peak sensory level is attained.  
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Table 5: GRADING OF MOTOR BLOCK 
 
 
Grading of  
Motor Block 
Group A Group B 
No. % No. % 
0 - - - - 
1 - - - - 
2 22 44 - - 
3 28 56 50 100 
Total 50 100 50 100 
‘p’ 0.0001 
Significant 
 
In group A 44% attained grade 2 block and 56% attained grade 3 block.  
In group B 100% attained grade 3 block. 
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Table 6 : TIME OF ONSET OF SENSORY BLOCK  
(IN MINUTES) 
 
 
Time of onset of sensory 
block  
(in minutes) 
 
Group A 
 
Group B 
Range 
Mean 
S.D. 
Value 
5 – 15 minutes 
10.2 minutes 
2.8 minutes 
10.2 ± 2.8 
3 – 7 minutes 
4.2 minutes 
1.0 minutes 
4.2 ± 1.0 
‘p’ 0.0001 
Significant 
 
The average time taken for onset of sensory block is 10.2 minutes in  
group A and 4.2 minutes was shown in group B.  The p value was 
0.0001 which was significant. 
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Table 7 : TOTAL DURATION OF SENSORY BLOCK 
(IN MINUTES) 
 
Total duration of  
Sensory Block 
(in minutes) 
 
Group A 
 
Group B 
Range 
Mean 
S.D. 
Value 
100– 230 minutes 
145.9 minutes 
34.8 minutes 
145.9 ± 34.8 
135 – 180 minutes 
152.8 minutes 
9.1 minutes 
152.8 ± 9.1 
‘p’ 0.145 
Not Significant 
 
 
 In this table the duration of sensory block in group A was 145.9 
minutes   and in group B is 152.8 minutes. The p value was 0145 which 
was not significant. 
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Table 8 : ONSET TIME OF MOTOR BLOCK (IN MINUTES) 
 
Onset Time of Motor 
Block  
(in minutes) 
 
Group A 
 
Group B 
Range 
Mean 
S.D. 
Value 
10– 20 minutes 
14.3 minutes 
3.1 minutes 
14.3 ± 3.1 
6 – 10 minutes 
9.3 minutes 
1.0 minutes 
9.3  ± 1.0 
‘p’ 0.0001 
Significant 
 
 In Table 8 and 9 the onset of motor block distribution in both 
groups were depicted. The p value was 0.0001, which was significant. 
The onset of motor block (time to achieve a bromage score of 3) was 
significantly faster in bupivacaine group of 9.3 minutes when compared 
with ropivacaine of 14.3 minutes.  
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Table 9 : TOTAL DURATION OF MOTOR BLOCK 
 (IN MINUTES) 
 
Total duration of  
Motor Block  
(in minutes) 
 
Group A 
 
Group B 
Range 
Mean 
S.D. 
Value 
80– 240 minutes 
137.2 minutes 
35.5 minutes 
137.2 ± 35.5 
100 – 300 minutes 
204.4 minutes 
37.2 minutes 
204.4 ± 37.2 
‘p’ 0.0001 
Significant 
 
 The table shows shorter duration of motor block in group A of 
137.2 ± 35.5 with significant p value. 
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Table 10 : BASELINE HEMODYNAMICS 
  
 
 
          Parameter 
Group A Group B  
‘p’ 
Mean S.D. Mean S.D. 
Pulse rate 85.7 17.0 84.3 14.6 0.7587 Not significant
Respiratory rate 13.36 1.68 13.16 1.3 0.6141 Not significant
Mean Arterial 
Pressure 
87.3 17.5 91.3 18.1 0.2323 Not significant
 
 
 The study showed stable hemodynamic status with decreased 
incidents of hypotension and insignificant ‘P’ value. 
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Table 11 : SPO2 
 
SPO2 Group A Group B 
Range 
Mean 
S.D. 
Value 
97 – 99 
97.98 
0.59 
97.98 ± 0.59 
97 – 99 
98.04 
0.45 
98.04 ± 0.45 
‘p’ 0.8009 
Not Significant 
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DISCUSSION 
 
M. Mantouvalou S Rali et al in the study to compare the 
aneasthetic efficacy and safety of three local anaesthetic agents namely 
15mg of racemic bupivacaine, ropivacaine and levobupivacaine in 
patients undergoing lower abdominal surgeries showed no significant 
difference in duration of sensory block between the groups. It stated 
delayed onset of 12 ± 5 minutes and faster recovery of motor block of 
100 ±  34 minutes  in ropivacaine group as seen in our study.  
 
 Kim S.Khaw et al., in their study compared 25mg of intrathecal   
hyperbaric and isobaric solution of ropivacaine in caesarean section. The 
onset of sensory block in isobaric group was 11.4 mins which was 
comparable to our study of 10 mins. Similarly the onset of motor block 
in isobaric ropivacaine group was 13.8 mins which was comparable to 
our study of 14.3 mins. The duration of sensory block and motor block 
was 216 mins and 184 mins where as in our study it was 145.2 mins and 
137.2 mins and the difference in this results was due to usage of  higher 
dose of 25mg of isobaric ropivacaine in their study.     
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Jean Marc, Malinovsky et al in their study compared 15mg of 
intrathecal isobaric ropivacaine with 10mg of isobaric bupivacaine in 
patients scheduled for transurethral resection of bladder or prostate. The 
study showed  no difference in hemodynamic effects between their 
groups as correlated with our study. The study reported similar intensity 
and the duration of motor block with isobaric ropivacaine was 165 mins 
and that of bupivacaine was 184 mins. The difference in the duration in 
the motor block in the above study is comparable to our results. 
 
Helena Kallio et al., conducted a study in 90 ambulatory lower 
extremity surgery patients who received plain solution of 2ml of 1% , 
0.75% ropivacaine and 0.5% bupivacaine.  It reported the median onset 
and duration of motor block in 15mg plain ropivacaine group was 20 
mins and 150 mins  which were comparable to 14.3 mins and 137.2 
mins in our study. The onset and duration of sensory block in 15mg 
ropivacaine group was 10 mins and 150 mins which were comparable to 
our study of 10 mins and 145.2 mins. The rationale for dose selection in 
this study was due to duration of action of ropivacaine in spinal 
anesthesia is approximately 50% to 67% that of bupivacaine, so that 
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patients could mobilise faster in both ropivacaine and bupivacaine 
groups.  
 
Furthermore, Gautier et al compared the effects of intrathecal 
administration of 8mg of isobaric bupivacaine, 8mg levobupivacaine or 
12mg ropivacaine all combined with sufentanil 2.5micrograms in 
patients undergoing caesarean delivery. Gautier selected the dose in his 
study under the hypothesis that three times of ropivacaine dose is 
equivalent to two times of bupivacaine. The onset and duration of motor 
block in ropivacaine group of their study was 14 mins and 116 mins 
which was comparable to 14.3 mins and 137.2 mins in our study. The 
onset and duration of motor block in bupivacaine group  of   their study 
was 9 mins and 142 mins where as it was 4 mins and 204 mins in our 
study. The difference in the duration of motor block between their and 
our study may be due to lower dose of bupivacaine used in their study.  
 
P.D.W fettes, G. Hocking et al conducted a study in 40 patients 
undergoing elective perineal surgery under spinal anaesthesia receiving 
either 15mg of plain ropivacaine or 15mg of hyperbaric ropivacaine. 
The onset of sensory block in isobaric ropivacaine group was 10 mins 
 53
which was comparable to our study of 10 mins. The duration of motor 
and sensory block in isobaric ropivacaine group was 180 mins and 270 
mins. Thus showing shorter duration of motor block than sensory block 
in ropivacaine as in our study. The study showed rapid onset of motor 
block of 5 mins and its recovery of 120 mins. The difference in the 
speedy onset and recovery of motor block in hyperbaric versus isobaric 
ropivacaine group is attributed to the baricity of the solution. 
 
McNamee et al compared 17.5mg of plain ropivacaine with 17.5 
mg plain bupivacaine in patients undergoing total hip arthroplasty under 
spinal anaesthesia. The onset of sensory block in both groups was 2 
mins. But in our study, it was 10 mins in ropivacaine and 4 mins 
bupivacaine. The difference in due to method of testing of sensory loss 
to ice in the above study. The duration of motor block is 130 mins in 
ropivacaine group which was comparable to our study of 137.2 mins. 
The duration of motor block in bupivacaine group was 230 mins where 
as  204mins in our study. Thus the above study showing shorter duration 
motor block in ropivacaine group as seen in our study. The duration of 
sensory block in the study was 180 mins in ropivacaine group and 110 
mins in bupivacaine group where as 145.9 mins and 152 mins 
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respectively in our study.  The difference in the duration of motor and 
sensory block of bupivacaine group between their and our study may be 
attributed to different dosage used in their study.   
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SUMMARY 
This study was conducted to compare the anaesthetic efficacy of 
intrathecal isobaric 0.5% ropivacaine with isobaric 0.5% bupivacaine in 
lower abdominal surgeries, in 100 ASA  grade I and II patients of both 
sexes in the age group of 19-68 years undergoing elective lower 
abdominal surgery under spinal anaesthesia. After getting ethical 
committee approval and informed written consent from the patients, 100 
patients were allocated into two groups of 50 patients each. The baseline 
pulse rate and mean arterial pressure were recorded. The first group A 
received 3ml of isobaric 0.5% ropivacaine (5mg/ml) and the second 
group received 3ml of isobaric 0.5% bupivacaine intrathecally. The 
pulse rate, mean arterial pressure , the onset of sensory and motor block, 
duration of sensory and motor block were recorded in both groups. The 
results were analysed statistically using epidemiologically information 
package. 
 
On comparison of data we have found that the intrathecal isobaric 
0.5% ropivacaine produces delayed onset, but similar duration of 
sensory block and a statistically significant shorter duration of motor 
block. The hemodynamics and height of block similar in both groups.      
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CONCLUSION 
  
We conclude from this study, that the intrathecal administration 
of 3ml of 0.5% isobaric ropivacaine when compared to 3ml of 0.5% 
isobaric bupivacaine, produces delayed onset but similar duration of 
sensory block (analgesia), and a statistically significant shorter duration 
of motor block. The hemodynamics and height of block (peak sensory 
level) are similar.  
 
Though the onset of sensory block is delayed, because of the 
effects on motor block, we consider ropivacaine can be a better choice 
for ambulatory anaesthesia. 
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PROFORMA 
 
NAME:    Age /Sex:  I.P.No: Ht:  Wt: 
      Duty Anaesthesiologist: 
ASA Physical Status: 
 PR:   BP:  RR:  CVS:  
 RS: 
Blood Investigations: 
Hb%:   RBS:  Urea:  creatinine  grouping & Typing 
Intraop - Group A & B 
Position and site of Injection : 
Time of Injection of drug  : 
Volume of drug injected  : 
Time of onset of sensory block-  Loss of sensation with pinprick test  
      with 21 G im needle. 
Maximum level of cephalad block: 
Time of onset of motor block : 
Duration of Sensory block : 
Duration of procedure  : 
Degree and duration of motor block: 
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Assessed by Bromage scale : 
‘0’ - No motor block (Movement of limbs) full flexion of  
  knees, feet able to lift extended leg. 
‘1’ - Unable to lift the extended leg. (Just flex knees and feet) not  
hip. 
‘2’ - In ability to flex knees, but flexion of feet possible. 
‘3’      - In ability to flex ankle,unable to move leg, complete motor 
paralysis. 
 
PR: Mean Arterial Pressure:  RR:  SPO2: 
 
Side effects and Complication: 
Insufficient block : 
Any discomfort : Nausea, vomiting,pruritis,pain 
Hypo tension > 30% fall systoloc Bp 
Bradycardia  < 50/mt 
Shivering 
Post of Headache & Backache 
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No GROUP Age Sex IP No DM HTN 
 
 
IHD COPD OTHERS PR RR MAP 
Time of 
onset 
of S.B. 
Peak 
sensory 
leve l 
Total 
duration 
of S.B. 
Time 
of 
onset 
of MB 
Total 
duration 
of MB 
grade 
of 
motor 
block 
Duration 
of 
surgery 
SPO2 ADVERSE EFFECTS 
1 A 22 F 1092597 - - - - - 88 14 108 5.5 T8 200 10 240 3 95 98  
2 A 25 M 1094118 - - - - - 81 12 108 7 T8 145 12 150 3 100 98  
3 A 35 F 1095381 - - - - - 90 16 90 6.5 T8 110 16 180 3 120 98  
4 A 28 F 1095403 - - - - - 108 12 60 10 T6 100 13 200 3 90 98 Hypotension 
5 A 19 M 1095388 - - - - - 72 13 70 12 T12 150 15 90 2 110 97 
Insufficient 
Block 
6 A 29 M 1092590 - - - - - 86 15 74 11 T8 170 18 130 3 120 98  
7 A 45 F 1094110 - - - - - 70 14 78 6 T8 130 10 180 3 95 98  
8 A 60 M 1095413 1 - 1 - - 70 12 90 13 T8 115 12 170 3 100 98  
9 A 40 M 1095340 - - - - - 68 12 103 10 T8 200 15 160 3 90 98  
10 A 39 M 1094000 - - - - - 90 11 108 7 T8 180 14 120 3 120 99  
11 A 20 F 1092595 - - - - - 100 12 58 9 T8 100 11 100 3 110 98 Hypotension 
12 A 32 M 1094114 - - - - - 78 14 110 12 T8 110 10 120 3 90 98  
13 A 19 M 1092598 - - - - 1 88 16 96 14 T8 140 10 96 3 100 98  
14 A 66 M 1094116 - 1 - 1 - 118 16 56 5 T8 115 12 135 3 120 98  
15 A 33 F 1090952 - - - - - 86 12 92 8 T8 120 12 100 3 95 98 Hypotension 
16 A 28 M 1092500 - - - - - 90 14 112 15 T8 180 15 150 3 100 98  
17 A 45 M 1094008 - - - 1 - 74 12 110 13 T8 140 20 180 3 110 99  
18 A 42 M 1095400 - - - - - 70 13 88 11 T8 120 16 135 3 120 98  
19 A 59 M 1094111 1 - - - - 68 16 80 10 T12 160 18 100 2 90 98 
Insufficient 
Block 
20 A 38 F 1095421 - - - - - 64 15 70 12 T8 160 10 140 3 95 98  
21 A 45 M 1095499 - - - - - 84 14 92 10 T8 115 10 140 3 95 98  
22 A 40 M 1095361 - - - - - 90 12 90 9 T8 180 12 160 3 95 98  
23 A 23 M 1094021 - - - - - 118 11 60 7 T2 180 16 110 3 100 99  
24 A 36 M 1092596 - - - - - 130 13 61 6 T8 160 15 110 3 120 98 Hypotension 
25 A 45 F 1095431 - - - - - 94 15 103 13 T8 150 18 180 3 140 98 Hypotension 
26 A 47 F 1095371 1 - - - - 88 14 105 15 T8 100 20 160 3 100 98  
27 A 65 M 1092561 - 1 - - - 66 16 70 14 T8 200 16 98 3 90 98  
28 A 35 M 1095499 - - - - - 116 10 80 9 T8 120 20 110 3 160 97  
MASTER CHART 
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29 A 30 M 1095380 - - - - - 90 12 84 13 T8 140 10 140 3 60 98  
30 A 51 M 1094331 - 1 - 1 - 100 13 110 12 T8 200 14 115 3 70 98  
31 A 36 M 1095331 - - - - - 84 16 102 11 T12 100 15 160 2 85 98  
32 A 28 F 1095402 - - - - - 90 14 108 9 T8 120 12 80 2 90 98 
Insufficient 
Block 
33 A 46 M 1094008 - - - - - 72 12 98 10 T8 120 14 120 2 115 99  
34 A 60 M 1092590 - - 1 - - 70 11 86 10 T8 100 18 110 2 60 98  
35 A 57 M 1095300 - 1 - 1 - 88 13 74 15 T8 150 18 90 2 80 98  
36 A 40 F 1095381 - - - - - 118 14 62 9 T8 230 14 160 2 45 98  
37 A 38 M 1095431 - - - - - 74 16 78 12 T8 100 12 190 2 60 97 Hypotension 
38 A 22 F 1094312 - - - - - 120 15 57 6 T8 160 18 185 2 65 98  
39 A 43 M 1092583 - - - - - 116 14 108 8 T8 200 16 175 2 75 98 Hypotension 
40 A 34 M 1094009 - - - - - 68 12 102 10 T8 170 12 105 2 80 98  
41 A 59 M 1095370 - - - - - 70 11 110 9 T8 140 13 100 2 100 98  
42 A 46 F 1095414 - - - - - 84 12 90 11 T8 120 15 154 2 65 99  
43 A 28 M 1095300 - - - - - 80 12 68 13 T8 115 18 130 2 60 98  
44 A 36 M 1095418 1 - - - - 78 16 70 10 T8 140 11 140 2 60 98  
45 A 60 F 1095384 - - - 1 - 72 14 100 15 T8 120 15 160 2 100 98  
46 A 58 M 1095411 - - - - - 70 11 102 13 T8 190 20 130 2 110 98  
47 A 43 F 1093396 - - - - - 86 12 70 9 T8 180 11 100 2 75 98  
48 A 27 M 1095312 - - - - - 74 13 80 10 T8 170 12 100 2 85 97  
49 A 59 M 1095391 - - - - - 68 14 84 6 T8 100 15 180 2 90 98  
50 A 40 M 1094021 - - - - - 70 15 100 10 T8 180 18 95 2 100 98  
51 B 30 F 1092241 - - - - - 88 12 109 4 T8 155 8 100 3 85 98  
52 B 32 M 1094401 - - - - - 72 14 60 3 T6 150 9 185 3 120 98  
53 B 22 M 1095503 - - - - - 90 16 78 5 T6 155 10 225 3 110 98  
54 B 25 F 1096402 - - - - - 98 14 70 6 T8 150 8 165 3 115 97 Hypotension 
55 B 27 M 1092201 - - - - - 78 11 80 3 T8 155 9 240 3 100 98  
56 B 30 M 1093567 - - - - - 60 13 90 4 T8 150 10 190 3 90 98  
57 B 36 M 1092234 - 1 - 1 - 58 14 92 3 T6 145 10 210 3 95 98 Shivering 
58 B 42 F 1093421 - - - - - 101 15 110 5 T6 135 6 260 3 105 98  
59 B 19 F 1094562 - - - - - 56 16 106 6 T6 165 10 240 3 110 99  
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60 B 56 M 10933227 - - - - - 60 12 105 6 T8 155 10 230 3 120 98 Shivering 
61 B 29 F 1092634 - - - - - 62 12 60 5 T8 145 10 180 3 95 98  
62 B 63 M 1092464 1 - - - - 79 14 106 3 T6 165 8 160 3 100 98  
63 B 46 M 1093404 - - - - - 74 13 100 4 T8 160 10 150 3 115 98  
64 B 40 F 1095545 - - - - - 96 11 103 5 T8 150 10 160 3 125 98 Hypotension 
65 B 54 M 1092586 - - - - - 80 12 104 3 T8 140 10 180 3 120 98  
66 B 55 M 1092602 - - - - - 84 13 110 4 T8 155 10 190 3 105 99 Shivering 
67 B 58 M 1093495 - - - - - 76 14 60 5 T8 150 8 195 3 85 98  
68 B 60 M 1092293 1 1 - 1 - 60 14 106 3 T8 180 10 210 3 90 98 Shivering 
69 B 29 F 1093413 - - - - - 110 14 108 3 T6 165 10 160 3 75 98  
70 B 36 M 1092753 - - - - - 78 12 106 3 T8 160 10 190 3 90 98  
71 B 41 F 1094424 - - - - - 62 11 104 4 T8 155 8 210 3 105 98 Hypotension 
72 B 37 M 1095453 - 1 - - - 82 14 64 5 T6 160 9 215 3 110 97  
73 B 42 M 1092376 - - - - - 88 12 90 6 T8 150 10 220 3 120 98  
74 B 53 M 1093534 - - - - - 90 13 78 7 T8 170 10 240 3 95 98  
75 B 61 M 1094615 - - - - 1 92 12 84 3 T8 165 10 225 3 105 98 Hypotension 
76 B 55 M 1092661 - - - - - 78 14 64 3 T8 155 10 225 3 90 99  
77 B 68 M 1093552 - - - - - 99 15 90 4 T6 160 8 200 3 95 98  
78 B 39 M 1092562 - - - - - 76 12 68 4 T6 150 10 190 3 85 98 Hypotension 
79 B 44 M 1093244 - - - - - 84 13 62 4 T8 155 8 175 3 90 98  
80 B 43 F 1095434 - - - - - 88 12 106 5 T8 150 10 180 3 100 97  
81 B 49 M 1094314 - - - 1 - 86 11 60 5 T6 145 10 185 3 95 98  
82 B 57 M 1093573 - - - - - 76 12 106 3 T8 140 8 200 3 85 98  
83 B 30 M 1092303 - - - - - 106 12 104 4 T8 155 10 200 3 80 98  
84 B 36 M 1094363 - - - - - 92 11 106 4 T8 165 10 190 3 95 98 Hypotension 
85 B 37 M 109249 - - - - - 94 12 108 4 T8 145 8 175 3 100 99  
86 B 40 F 1094603 1 1 - - - 96 13 110 5 T8 150 10 180 3 115 98  
87 B 60 M 1092544 - - - - - 76 11 60 5 T8 155 10 185 3 85 98  
88 B 49 M 1092496 - - - - - 108 14 78 3 T8 145 10 200 3 80 98 Hypotension 
89 B 54 M 1094544 - - - - - 75 14 94 3 T8 140 8 225 3 75 98  
90 B 64 M 1094377 - - - - - 88 14 96 5 T6 145 9 180 3 85 99  
91 B 40 F 1095574 - 1 - - - 90 14 84 4 T6 165 10 250 3 100 98  
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92 B 61 M 1094406 - - - - - 120 14 80 5 T6 155 9 265 3 80 98  
93 B 38 M 1092384 - - - - - 78 14 84 3 T8 150 8 270 3 90 98 Hypotension 
94 B 42 F 1094594 - - - - - 87 14 98 4 T8 145 10 300 3 95 98  
95 B 59 M 1093655 - 1 - - - 85 14 70 4 T8 140 10 280 3 90 99  
96 B 45 M 1092424 - - - 1 - 94 14 108 5 T8 160 10 250 3 85 98 Shivering 
97 B 65 M 1094655 - - - - - - - 110 5 T6 140 8 180 3 85 98  
98 B 53 F 1095475 - - - - - 82 14 120 4 T6 150 8 175 3 95 98  
99 B 47 M 1093546 - 1 - - - 74 14 112 3 T8 155 8 190 3 100 97  
100 B 50 F 1092376 - - - - - 98 14 105 3 T8 140 10 240 3 110 98  
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